Test & Monitor Invasive Fungal Infections for Immunocompromised Patients
Antifungal Test Results in time to make a difference
If you suspect your bone marrow transplant (BMT/HSCT) immunocompromised or critical patient has an invasive fungal infection (IFI), one day can be the difference between life and death. The successful management of invasive fungal infections continues to pose a difficult challenge for physicians treating these critical patients, and mobidity and mortality due to IFI remains unacceptably high.1 Triazole antifungal drugs are commonly used to either prevent or treat IFI in at-risk patients. However, extensive intra- and inter-patient variability is observed in the pharmacokinetics of triazole antifungal drugs. This variability supports quantitative monitoring, i.e., therapeutic drug monitoring of triazole blood levels.1,2 With clinical testing and faster turnaround time, you can better support your patient's continuum of care - from the onset of symptoms to managing dosage.
Treat IFIs Faster, Reduce Mortality3,4
When timing is critical, can you afford not to know your patient's antifungal drug blood levels? A delay in antifungal treatement could be an increased chance of mortality.3,4
Manage Drug Levels, Keep Patients in Therapeutic Range5
Relationship between voriconazole dosage and blood levels. In this study, up to 35% of patient samples were outside the therapeutic range.5
Testing to individualize your approach to invasive fungal infections
With testing that aids in differential diagnosis, faster treatment and drug level monitoring, your patient will do better and the hospital can lower costs. Depend on Viracor-IBT for clinical testing and rapid turnaround time that makes a difference.
Our fungal tests include: Fungitell 1-3-B-D-Glucan assay, Aspergillus Galactomannan EIA, Aspergillus PCR panel, Candida Real-time PCR, ALPHA Histoplasma Antigen EIA, Mucorales Real-time PCR, Pnemocystis jiroveci qPCR and more.
Antifungal drug level monitoring testing includes: Voriconazole LC-MS/MS, Posaconazole LC-MS/MS, Itraconazole LC-MS/MS and Isavuconazole (CRESEMBA) LC-MS/MS.
For more information on our fungal testing, please call
client services at 800.305.5198.
1Andes D, Pascual A, Marchetti O, Antifungal Therapeutic Drug Monitoring: Establishing and Emerging Indications: Antimicrob Agents Chemother. 2009 Jan; 53(1):24-34.
2Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008 Jan; 61(1):17-25.
3Assoc of Cape Cod, Fungitell Assay Instructions for Use. 2011 (Feb) Garey et al, Clin Infect Dis. 2006; 43:25-31. Karageorgopoulos et al. Clin Inf Dis. 2011; 52:750-770.
4Luong ML et al. Clin Inf Dis. 2012; 52 (10):1218-1226. Nguyen ML, Wissel MC et al. Clin Inf Dis. 2012; 54:1240-1248.
5Andres Pascual, Thierry Calandra, Saskia Bolay, Thierry Buclin, Jacques Bille, and Oscar Marchetti, Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, 2008:46(2);204 by permission of Infectious Diseases Society of America.